Skip to main content

Table 1 Subject demographic characteristics and severity classifications: development data

From: Using medication utilization information to develop an asthma severity classification model

Variables

All asthma, (n = 3593)

Classified by Asthma severity, n (%)

p-value

Stage 1 (n = 2253, 62.71%)

Stage 2 (n = 199, 5.54%)

Stage 3 (n = 819, 22.79%)

Stage 4 (n = 322, 8.96%)

Gender, n(%)

     

0.1548

 Female

2101 (58.47)

1285 (57.04)

123 (61.81)

498 (60.81)

195 (60.56)

 

 Male

1492 (41.53)

968 (42.96)

76 (38.19)

321 (39.19)

127 (39.44)

 

Age, n(%)

     

<.0001

 18–34

880 (24.49)

511 (22.68)

55 (27.64)

231 (28.21)

83 (25.78)

 

 35–44

609 (16.95)

355 (15.76)

46 (23.12)

143 (17.46)

65 (20.19)

 

 45–54

660 (18.37)

406 (18.02)

39 (19.60)

148 (18.07)

67 (20.81)

 

 55–64

619 (17.23)

405 (17.98)

31 (15.58)

144 (17.58)

39 (12.11)

 

65

825 (22.96)

576 (25.57)

28 (14.07)

153 (18.68)

68 (21.12)

 

CCI, Mean(SD)

0.39 (0.85)

0.41 (0.85)

0.28 (0.84)

0.34 (0.73)

0.38 (1.05)

0.0435

Obesity, n(%)

10 (0.28)

9 (0.40)

0 (0.00)

1 (0.12)

0 (0.00)

0.6141

Sinusitis, n(%)

40 (1.11)

21 (0.93)

2 (1.01)

15 (1.83)

2 (0.62)

0.1808

GERD, n(%)

11 (0.31)

10 (0.44)

0 (0.00)

0 (0.00)

1 (0.31)

0.2207

Medication utilization, n(%)

 ICS/LABA

866 (24.10)

0 (0.00)

0 (0.00)

660 (80.59)

206 (63.98)

<.0001

 ICS

309 (8.60)

0 (0.00)

199 (100.0)

89 (10.87)

21 (6.52)

<.0001

 OCS

366 (10.19)

0 (0.00)

0 (0.00)

203 (24.79)

163 (50.62)

<.0001

 SABA

822 (22.88)

423 (18.77)

54 (27.14)

267 (32.60)

78 (24.22)

<.0001

 SAMA

111 (3.09)

49 (2.17)

5 (2.51)

43 (5.25)

14 (4.35)

0.0001

 SABA/SAMA

155 (4.31)

71 (3.15)

9 (4.52)

56 (6.84)

19 (5.90)

<.0001

# of patient having acute exacerbation, n(%)

349(9.71)

184(8.17)

19(9.55)

98(11.97)

48 (14.91)

0.0001

 Hospitalization

52 (1.45)

28 (1.24)

4 (2.01)

9 (1.10)

11 (3.42)

0.0144

 Emergency department visit

160(4.45)

79(3.51)

8(4.02)

54(6.59)

19(5.90)

0.0016

 Short-acting drug

218(6.07)

115(5.10)

9(4.52)

63(7.69)

31(9.63)

0.0015

  1. CCI Charlson Comorbidity Index, GERD Gastroesophageal reflux disease, ICS inhaled corticosteroid, OCS oral corticosteroid, SABA short-acting inhaled β2-agonist, LABA long-acting inhaled β2-agonist, SAMA short-acting muscarinic receptor antagonists